The Academy of Managed Care Pharmacy (AMCP) is pleased provide comments to the Centers for Medicare & Medicaid Services (CMS) in response to the proposed rule “Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency [CMS-4187-P]” published in the Federal Register on October 18, 2018.
On November 26, The Centers for Medicare and Medicaid Services (CMS) issued a new proposed rule outlining potential policies that are intended to lower the cost of prescription drugs through tools that allow prescription drug plans to negotiate prices and by improving access to costly drugs through reduction of out-of-pocket costs for beneficiaries.
On Nov 1, The Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that updates Medicare Advantage (MA or Part C) and the Medicare Prescription Drug Benefit Program (Part D).
On November 1, 2018, the Centers for Medicare & Medicaid Services (CMS) finalized its rule for the 2019 Physician Fee Schedule (PFS) and the Quality Payment Program (QPP).
On October 30, 2018, the Centers for Medicare and Medicaid Services (CMS) published an Advanced Notice of Proposed Rulemaking (ANPRM) for a potential International Pricing Index (IPI) Model for Medicare Part B Drugs.
On October 18, 2018, the Centers for Medicare & Medicaid Services (CMS) issued a new proposed rule entitled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency.
The Academy of Managed Care Pharmacy (AMCP) thanks Congress for its dedication to combatting the opioid epidemic. The importance of H.R. 6 increases as the number of preliminary CDC reported overdose deaths rise (72,000 overdose deaths in 2017). Both pieces of legislation passed by the House and Senate will advance patient treatment and recovery initiatives, improve prevention of opioid addiction, protect communities, and increase education initiatives for patients and providers.